Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis

Journal of Hepatology

Volumn 27, Issue 1, 1997, Pages 136-142

  Vuoristo, Matti ^b   Färkkilä, Martti ^b   Gylling, Helena ^b   Karvonen, Anna Liisa ^b   Leino, Rauli ^b   Lehtola, Juhani ^b   Mäkinen, Judit ^a   Mattila, Jorma ^b   Tilvis, Reijo ^b   Miettinen, Tatu A ^b  

^a PEIJAS HOSPITAL   (Finland)

^b NONE

Author keywords

Apolipoprotein E polymorphism; Bile acids; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLCHICINE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOCHONDRION ANTIBODY; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; FINLAND; GENE FREQUENCY; HEPATITIS; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PRURITUS;

EID: 0342981537     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80293-0     Document Type: Article

References (37)

1. Sherlock S, Dooley J. Diseases of the Liver and Biliary System. 1993;236-248 Blackwell Scientific Publications, Oxford.
2. James SP, Hoofnagle JH, Strober W, Jones EA. Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med. 99:1983;500-512.
3. Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology. 100:1991;822-833.
4. Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hübner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 97:1989;1268-1274.
5. Poupon RE, Poupon R, Balkaus B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 330:1994;1342-1347.
6. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 106:1994;1284-1290.
7. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
8. Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med. 315:1986;1448-1454.
9. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. i:1987;834-836.
10. Vuoristo M, Färkkilä M, Karvonen A-L, Leino R, Lehtola J, Mäkinen J, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 108:1995;1470-1478.
11. Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med. 120:1994;1026-1036.
12. Juvonen T, Kervinen K, Kairaluoma MI, Lajunen LHJ, Kesäniemi YA. Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology. 104:1993;1806-1813.
13. Kesäniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest. 80:1987;578-581.
14. Gylling HK, Miettinen TA. Bile acid metabolism regulates different cholesterol absorption in apo E phenotypes. Gastroenterology. 108:1995;A1077. (suppl).
15. Ehnholm C, Lukka M, Kuusi T, Nikkilä E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 27:1986;227-235.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
17. Kurki P, Miettinen A, Linder E, Pikkarainen P, Vuoristo M, Salaspuro M. Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance. Gut. 21:1980;878-884.
18. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen EA. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 28:1987;455-463.
19. Davignon J, Gress RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8:1988;1-21.
20. Lehtimäki T, Moilanen T, Viikari J, Akerblom HK, Ehnholm C, Rönnemaa T, et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res. 31:1990;487-495.
21. Kuusisto J, Koivisto K, Kervinen K, Mykkänen L, Helkala E-L, Vanhanen M, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. Br Med J. 309:1994;636-638.
22. Louhija J, Miettinen HE, Kontula K, Tikkanen MJ, Miettinen TA, Tilvis RS. Aging and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E4 phenotype in centenarians. Arterioscler Thromb. 14:1994;1084-1089.
23. Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterization of patients with a complete biochemical response to ursodeoxycholic acid. Gut. 36:1995;935-938.
24. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 22:1995;759-766.
25. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 16:1992;358-364.
26. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 11:1990;12-15.
27. Hillaire S, Boucher E, Calmus Y, Gane P, Ballet F, Franco D, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology. 107:1994;781-788.
28. Miettinen TA. Impact of apo E phenotype on the regulation of cholesterol metabolism. Ann Med. 23:1991;181-186.
29. Gylling H, Färkkilä M, Vuoristo M, Miettinen TA. Metabolism of cholesterol and low and high density lipoproteins in primary biliary cirrhosis. Hepatology. 21:1995;89-95.
30. Ponz de Leon M, Carulli N, Loria N, Iori R, Zironi F. Cholesterol absorption during bile acid feeling. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology. 78:1980;214-219.
31. Hardison WGM, Grundy SM. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology. 87:1984;130-135.
32. Leiss O, von Bergmann K, Streicher U, Strotkoetter H. Effect of three different dihydroxy bile acids on intestinal cholesterol absorption in normal volunteers. Gastroenterology. 87:1984;144-149.
33. Curtiss LK, Edgington TS. Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein. J Immunol. 116:1976;1452-1458.
34. Curtiss LK, Edgington TS. Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor, an immunoregulatory species of normal human serum low density lipoprotein. J Clin Invest. 61:1978;1298-1308.
35. Hui DY, Harmony JAK, Innerarity TL, Mahley RW. Immunoregulatory plasma lipoproteins: role of apoprotein E and apoprotein B. J Biol Chem. 255:1980;11775-11781.
36. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
37. Aouad K, Calmus Y, Nordlinger B, Myara A, Weills B, Poupon R. Immunosuppressive effects of endotoxin and bile acids in vivo in the rat. J Clin Invest. 26:1996;45-48.